Klaus Rose, Jane M Grant-Kels, Pasquale Striano, Emilio Russo, Earl B Ettienne
{"title":"Deception and Fraud in the Justification of \"Pediatric Drug Development\": A Challenge at the Interface of Medicine and Law.","authors":"Klaus Rose, Jane M Grant-Kels, Pasquale Striano, Emilio Russo, Earl B Ettienne","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>United States and European Union laws demand separate clinical studies in children as a condition for drugs' marketing approval. Justified by carefully framed pseudo-scientific wordings, more so the European Medicines Agency than the United States Food and Drug Administration, \"Pediatric Drug Development\" is probably the largest abuse in medical research in history. Preterm newborns are immature and vulnerable, but they grow. Adolescents are bodily no longer children. Younger children are not another species. Instead of reasonable dose-finding, most \"pediatric\" studies replicate at best what is known already; others withhold effective treatment and/or harm by substandard comparison, triggering \"pediatric\" drug labels and \"pediatric\" careers. Researching deception and fraud focuses currently on individuals. The mechanisms by which lawmakers and the public were and are deceived need elucidation in our increasingly complex society, including new types of conflicts of interest. Candidly addressing deception and fraud at the interface of medicine and law will help to unmask pseudoscience.</p>","PeriodicalId":45522,"journal":{"name":"Journal of Law and Medicine","volume":"31 3","pages":"635-644"},"PeriodicalIF":0.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Law and Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"LAW","Score":null,"Total":0}
引用次数: 0
Abstract
United States and European Union laws demand separate clinical studies in children as a condition for drugs' marketing approval. Justified by carefully framed pseudo-scientific wordings, more so the European Medicines Agency than the United States Food and Drug Administration, "Pediatric Drug Development" is probably the largest abuse in medical research in history. Preterm newborns are immature and vulnerable, but they grow. Adolescents are bodily no longer children. Younger children are not another species. Instead of reasonable dose-finding, most "pediatric" studies replicate at best what is known already; others withhold effective treatment and/or harm by substandard comparison, triggering "pediatric" drug labels and "pediatric" careers. Researching deception and fraud focuses currently on individuals. The mechanisms by which lawmakers and the public were and are deceived need elucidation in our increasingly complex society, including new types of conflicts of interest. Candidly addressing deception and fraud at the interface of medicine and law will help to unmask pseudoscience.
美国和欧盟的法律要求将单独的儿童临床研究作为药物上市许可的条件。在精心设计的伪科学措辞的支持下,“儿科药物开发”可能是医学研究史上最大的滥用,欧洲药品管理局(European Medicines Agency)比美国食品和药物管理局(United States Food and Drug Administration)更是如此。早产的新生儿还不成熟,很脆弱,但他们会成长。青少年在肉体上已不再是儿童。年幼的孩子不是另一个物种。大多数“儿科”研究最多只是重复已知的东西,而不是合理的剂量发现;还有一些人通过不合格的比较隐瞒了有效的治疗和/或伤害,引发了“儿科”药物标签和“儿科”职业。目前对欺骗和欺诈的研究主要集中在个人身上。在我们这个日益复杂的社会中,立法者和公众被欺骗和被欺骗的机制需要得到阐明,包括新型的利益冲突。坦率地处理医学和法律领域的欺骗和欺诈行为将有助于揭露伪科学。